Back to top
more

Virtus Biotech Clinical Trials ETF: (BBC)

(Delayed Data from NYSE) As of Nov 20, 2026 03:59 PM ET

$38.17 USD

38.17
53,413

-1.60 (-4.02%)

Volume: 53,413

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

After-Market: $38.55 +0.38 (1.00 %) 7:58 PM ET

Zacks News

Sweta Killa headshot

Top and Flop ETFs of Q1

We have highlighted the three ETFs each from the best and worst performing zones of first-quarter 2022.

Sweta Killa headshot

Top and Flop ETFs At Midway Q1

We have highlighted the five best-performing zones and their ETFs halfway through first-quarter 2022.

Sweta Killa headshot

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Sweta Killa headshot

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Sweta Killa headshot

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Sweta Killa headshot

Healthcare ETFs, Stocks That Gained Double Digits Last Week

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Sweta Killa headshot

Biotech ETFs Soars on Gilead-Immunomedics Deal

The acquisition will expand Gilead's portfolio of treatments for various types of cancer.

Sanghamitra Saha headshot

Why Small-Cap Biotech ETFs Are Good Long-Term Bets

Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.

Sweta Killa headshot

4 Best ETF Charts of Q1 Earnings

Below are four ETFs that buoyed up on strong earnings results.

Sweta Killa headshot

Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain

The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.